U.S. – FDA to review Pfizer booster for adults ‘as soon as possible’
The Food and Drug Administration (FDA) will likely authorise the Covid19 vaccine booster dose from Pfizer-BioNTech for all U.S. adults as soon as Thursday, according to a report.
The decision from the FDA will likely come before a U.S. Centers for Disease Control and Prevention (CDC) advisory panel meets on Friday to discuss expanding the eligibility for booster doses of Pfizer/BioNTech’s vaccine, currently allowed for select groups of people.
However, the majority of adults are already eligible to receive boosters. The FDA had already authorised boosters for anyone 65 and older who was vaccinated at least six months ago and for certain adults at high risk of infection or of severe disease.